Nurix Therapeutics is a biotechnology company that is leading the field of protein modulation to develop innovative medicines for cancer and inflammatory diseases. The company leverages its proprietary DELigase platform to create small molecule drugs that harness the activity of E3 ligases, enzymes crucial for protein degradation within cells. Nurix's approach involves both targeted protein degradation, which eliminates specific disease-causing proteins, and targeted protein elevation, which prevents protein degradation to raise levels of beneficial proteins. Through its advanced pipeline, Nurix aims to meet the unmet medical needs of patients by empowering the body's natural ability to fight disease.